Document is current
Any future updates will be listed below
-
Authors
Kang, HyunJun
Hoang, Dinh Hoa
Valerio, Melissa
Pathak, Khyatiben
Graff, William
LeVee, Alexis
Wu, Jun
LaBarge, Mark A.
Frankhouser, David
Rockne, Russell C.
Pirrotte, Patrick
Zhang, Bin
Mortimer, Joanne
Nguyen, Le Xuan Truong
Marcucci, Guido
-
Funding
Funding for this research was provided by:
Cherng Family Center for Integrative Oncology Research Pilot Program (2013557, 2013557, 2013557, 2013557, 2013557, 2013557, 2013557)
National Cancer Institute (P30CA33572, P30CA33572, P30CA33572, P30CA33572, P30CA33572, P30CA33572, P30CA33572, P30CA33572, P30CA33572, P30CA33572, P30CA33572, P30CA33572, P30CA33572, P30CA33572)
- License Information
-
More Information
Article History
Received: 12 November 2024
Accepted: 28 January 2025
First Online: 7 February 2025
Declarations
:
: For primary human samples, normal HMEC and TNBC samples were obtained from healthy donors and patients at the City of Hope National Medical Center (COHNMC) under City of Hope Institutional Review Board-approved banking protocols (#07047), or received from the Huntsman Cancer Institute (Utah, USA). All procedures were conducted in accordance with assurances filed with and approved by the Department of Health and Human Services and met the requirements of the Declaration of Helsinki.
: For animal studies, all mice were maintained in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited facility, and all experimental procedures adhered to federal and state government guidelines as well as institutional protocols approved by the Institutional Animal Care and Use Committee at City of Hope (IACUC #22043).
: W.G., L.X.T.N., and G.M. are shareholders of Ostentus Therapeutic Inc. The remaining authors declare that there is no conflict of interest regarding the publication of this article.
